NorthWest Biotherapeutics Inc (NWBO)

[notbrad]

if a pharma entity wants to win the China license or the Japan license and wants to get it against less competition they will move early, before the P3 results. I would not be surprised if a China licensing deal is in place prior to results.

Agreed that this is entirely plausible. Mesoblast, an Australian biotech developing stem cell treatments just entered into a partnership deal with Tasly Pharmaceuticals of China. This was done even before the completion of their ongoing phase 3 trial in the US. They also have a similar partnership with JCR in Japan. I believe this is just one of many examples which the Chinese are pursuing.

https://finance.yahoo.com/news/mesoblast-tasly-pharmaceutical-group-complete-100000740.html

And here's an interesting article on China's pursuit of biotech investments.

https://www.afr.com/business/health/china-resources-state-path-capital-fund-seeks-out-aussie-healthcare-companies-20181212-h190oh